Dedication - Dr. E. Donnall Thomas  by Appelbaum, Frederick R.
Don was born in a small Texas village on March 15,
1920, the son of a solo general practitioner. He remembers
as a child accompanying his father on house calls. As Don
has pointed out, together he and his father span the time
f rom horse and buggy house calls to modern high-tech
medicine. He received his B.A. and M.A. from the Univer-
sity of Texas, and more import a n t l y, that is where he met
Dottie, his wife and partner. In addition to raising 3 children
(and now 8 grandchildren), Dottie has provided invaluable
support for all of Don’s work, doing everything from assist-
ing in the laboratory to editing manuscripts and adminis-
trating grants. As has often been said, if Don is the father of
marrow transplantation, then surely Dottie is the mother.
Don entered Harvard Medical School in 1943, follow-
ing which he completed his internship and residency at
Peter Bent Brigham Hospital in Boston, spent time in the
Army, and trained in hematology under Dr. Clement Finch.
It was during medical school that Don first became inter-
ested in bone marrow and leukemia. At that time Sydney
Farber was first beginning to treat children for acute
leukemia and Don witnessed the very first patient whose
remission was induced with an anti-folate drug. While a
house officer and a fellow, Don also became interested in
factors that stimulate marrow function due to Allan Erslev’s
s e a rch for ery t h ropoietin. More important, he became aware
of the studies of Leon Jacobsen who showed that shielding
the spleen would protect mice from otherwise lethal irradia-
tion. When it was subsequently demonstrated by cytoge-
netic markers that the irradiation protection effect of mar-
row was due to the survival of living transplanted bone mar-
row cells, Don became convinced of the clinical potential of
marrow transplantation.
In 1955 Don moved to the Mary Imogene Basset Hos-
pital in Cooperstown, New York, an affiliate of Columbia
University, where he began working with Dr. Joseph Ferre-
bee on marrow transplantation both in humans and in the
dog. In 1957, Don published the first re p o rt showing that
complete remissions of leukemia could be achieved by treat-
ing patients with total body irradiation followed by infusion
of marrow from an identical twin. Attempts at that time to
expand this approach to patients without identical twins
w e re unsuccessful due to a lack of understanding of the
principles of histocompatibility, but these failures became
the stimulus for a long series of experiments using outbred
dogs as a model for human patients. Don was able to show
that it was possible to expose dogs to supralethal doses of
irradiation and rescue them by reinfusing their own marrow,
that the marrow could be cry o p re s e rved, and that a larg e
dose of peripheral blood could substitute for marro w. But
attempts at allogeneic transplantation continued to fail
because of graft-versus-host disease or graft rejection.
Don moved to the University of Washington in 1963 to
become the first head of the Division of Oncology. By the
mid 1960s he and his colleagues had developed techniques
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for ru d i m e n t a ry histocompatibility typing in the dog and
demonstrated that by selecting matched donors and using
posttransplant methotrexate it was possible to successfully
transplant marrow between matched littermates in almost
e v e ry case. By this time, significant pro g ress also was being
made in human HLA typing, let by Dausset, Payne, Amos
and others. In the late 1960s, Don made the decision to
re t u rn to the subject of allogeneic transplantation in humans,
w rote a program project grant that was funded by the
National Cancer Institute, and began to assemble a team of
physicians, nurses and support personnel that remains larg e l y
intact to this day. In November 1968, Dr. Robert Good and
his colleagues carried out the first marrow transplant from a
matched sibling for an infant with immunodefic i e n c y, and in
M a rch 1969 the Seattle team carried out the first matched
sibling transplant for a patient with advanced leukemia.
From the time of his arrival in Seattle until 1972, Don
and his small team were carrying out their laboratory and
clinical work at the Seattle Public Health Hospital. When
the Public Health Hospital was faced with closure by the
federal government, the program was temporarily moved to
Providence Hospital. In 1975, the team moved to the newly
c reated Fred Hutchinson Cancer Research Center, which
p rovided Don the opportunity to expand his program. In
1975, Don and his colleagues published a landmark paper in
the New England Journal of Medicine summarizing the fie l d
of allogeneic transplantation at that time and, in particular,
the early Seattle experience with transplantation for recur-
rent leukemia. He was able to demonstrate not only the fea-
sibility of the procedure, but also that a plateau had devel-
oped on the survival curve demonstrating that some patients
with refractory leukemia could actually be cured by marrow
transplantation. Don continued to lead the Clinical Division
of the Fred Hutchinson Cancer Research Center transplant
program until his partial retirement in 1989. He continues
to work, on average, about 3 days a week writing textbooks
and manuscripts, delivering lectures and participating in
research discussions at the Center.
For pioneering the bone marrow transplant procedure,
Don has appropriately received almost every possible award
including the Henry M. Stratton Award from the American
Society of Hematology, the Kettering Prize from General
Motors, the Karnofsky Aw a rd of the American Society of
Clinical Oncology, the Presidential Medal of Science Award
and, of course, the 1990 Nobel Prize in Medicine, which he
shared with Joseph Murray. On receipt of every award, Don
has been quick to point out that his work was very much a
team effort. He never fails to mention the contributions of
Rainer Storb, Dean Buckner, Reg Clift, Paul Neiman, Alex
Fefer and Bob Epstein, who helped form the original Seattle
Transplant Team. Ted Graham moved with Don fro m
Cooperstown and played an essential role in the animal
research. And, of course, Don never fails to credit the Nurs-
ing and Support staffs who have been so much a part of this
e ff o rt, and he always acknowledges the patients and their
families who have been true partners in his work.
In addition to his enormous scientific contributions,
Don has been a wonderful role model for those of us who
have had the great fortune to work with him. He has always
been focused, hardworking and uncompromising in his
a p p roach to clinical science. He is generous with his ideas
and quick to deflect praise to his co-workers. At the same
time, he can be a  demanding critic and holds others
accountable for their actions. While dedicating an enor-
mous amount of himself to a life in science, he has retained
a great deal of balance. He has always been generous with
his time as a visiting lecture r, providing service to pro f e s-
sional organizations and in support of local and intern a-
tional charities. He and his wife are avid and expert hunters
and fishers. And he has a close and loving family.
Don is a humble, almost shy man and I know he may
wince when he reads this. But I also know there are thou-
sands of patients, physicians and staff who would like to take
this opportunity to thank him both for what he has accom-
plished, and for the way he has done it. Thanks, Don.
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